Literature DB >> 12694516

Management of haemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates.

M Shibata1, M Shima, H Misu, Y Okimoto, J C Giddings, A Yoshioka.   

Abstract

Allergic reactions to concentrates containing factor IX (FIX) are serious complications in the treatment of haemophilia B patients with inhibitor. We have established a therapeutic protocol for such cases using an initial skin test followed by step-wise infusions of FIX concentrates under hydrocortisone cover. We have successfully treated three patients whose treatment with FIX had been suspended.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12694516     DOI： 10.1046/j.1365-2516.2003.00772.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


  9 in total

1.  Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice.

Authors:  Yingyu Chen; Jocelyn A Schroeder; Erin L Kuether; Guowei Zhang; Qizhen Shi
Journal:  Mol Ther       Date:  2013-08-23       Impact factor: 11.454

Review 2.  A Molecular Revolution in the Treatment of Hemophilia.

Authors:  John S S Butterfield; Kerry M Hege; Roland W Herzog; Radoslaw Kaczmarek
Journal:  Mol Ther       Date:  2019-11-13       Impact factor: 11.454

Review 3.  Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches.

Authors:  Shannon L Meeks; Glaivy Batsuli
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

4.  Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients.

Authors:  Anthony K Chan; Jayanthi Alamelu; Chris Barnes; Ampaiwan Chuansumrit; May-Lill Garly; Rikke Medom Meldgaard; Guy Young
Journal:  Res Pract Thromb Haemost       Date:  2020-07-29

5.  Platelet-targeted hyperfunctional FIX gene therapy for hemophilia B mice even with preexisting anti-FIX immunity.

Authors:  Jocelyn A Schroeder; Juan Chen; Yingyu Chen; Yuanhua Cai; Hongyin Yu; Jeremy G Mattson; Paul E Monahan; Qizhen Shi
Journal:  Blood Adv       Date:  2021-03-09

Review 6.  Desensitization and immune tolerance induction in children with severe factor IX deficiency; inhibitors and adverse reactions to replacement therapy: a case-report and literature review.

Authors:  Andrea Bon; Massimo Morfini; Alessandro Dini; Francesca Mori; Simona Barni; Sottilotta Gianluca; Maurizio de Martino; Elio Novembre
Journal:  Ital J Pediatr       Date:  2015-02-19       Impact factor: 2.638

Review 7.  Platelet-Targeted Gene Therapy for Hemophilia.

Authors:  Qizhen Shi
Journal:  Mol Ther Methods Clin Dev       Date:  2018-02-07       Impact factor: 6.698

8.  Clinical Care of Bone Health in Patients on the Immune Tolerance Induction's Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia.

Authors:  Zahra Rezaieyazdi; Hassan Mansouritorghabeh
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

Review 9.  International consensus recommendations on the management of people with haemophilia B.

Authors:  Daniel P Hart; Davide Matino; Jan Astermark; Gerard Dolan; Roseline d'Oiron; Cédric Hermans; Victor Jiménez-Yuste; Adriana Linares; Tadashi Matsushita; Simon McRae; Margareth C Ozelo; Sean Platton; Darrel Stafford; Robert F Sidonio; Andreas Tiede
Journal:  Ther Adv Hematol       Date:  2022-04-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.